317 related articles for article (PubMed ID: 32062791)
1. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
[TBL] [Abstract][Full Text] [Related]
2. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
3. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
4. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
6. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.
Sutherland JE; Hettinger JL; Chan A; Gilbert J; Warner GL; Davis WP
Nucleic Acid Ther; 2020 Feb; 30(1):33-49. PubMed ID: 31821125
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
[TBL] [Abstract][Full Text] [Related]
10. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
[TBL] [Abstract][Full Text] [Related]
11. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
[TBL] [Abstract][Full Text] [Related]
12. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
13. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
14. DISCOVERY: prevalence of transthyretin (
Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
[TBL] [Abstract][Full Text] [Related]
15. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
Campbell CM; Baiyee CAMT; Almaani S; Bumma N; Sharma N; LoRusso S; Redder E; Bittengle J; Pfund K; Friemer M; Tong M; Kahwash R; Efebera Y; Parikh S; Vallakati A
Am J Ther; 2023 Sep-Oct 01; 30(5):e447-e453. PubMed ID: 37713689
[TBL] [Abstract][Full Text] [Related]
17. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
[TBL] [Abstract][Full Text] [Related]
18. Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.
Zanazzi G; Arshad M; Maurer MS; Brannagan TH; Tanji K
J Clin Neuromuscul Dis; 2019 Mar; 20(3):120-128. PubMed ID: 30801482
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
